Patents by Inventor Edward A. MOTEA

Edward A. MOTEA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-natural nucleosides as theranostic agents
    Patent number: 9988680
    Abstract: A composition for monitoring DNA damage includes a 3-ethynyl-5-nitroindolyl-2?-deoxyribose compound or pharmaceutically acceptable salt thereof and a detectable moiety with a click-reactive functional group that is complementary to the alkyne group of the compound.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: June 5, 2018
    Assignee: Case Western Reserve University
    Inventors: Anthony J. Berdis, Irene Lee, Edward Motea
  • KUB5/HERA AS A DETERMINANT OF SENSITIVITY TO DNA DAMAGE
    Publication number: 20180057888
    Abstract: The present disclosure is directed to methods of detecting KUB5/HERA expression levels, copy number and mutation status, particularly in cancer cells. The methods permit physicians to tailor therapies to subject having certain genotypes/phenotypes, and to exclude therapies unlikely to be effective.
    Type: Application
    Filed: March 8, 2016
    Publication date: March 1, 2018
    Inventors: David A. BOOTHMAN, Edward A. MOTEA, Praveen PATIDAR, Julio MORALES
  • XRN2 AS A DETERMINANT OF SENSITIVITY TO DNA DAMAGE
    Publication number: 20170342503
    Abstract: The present disclosure is directed to methods of detecting XRN2 expression levels, copy number and mutation status, particularly in cancer cells. The methods permit physicians to tailor therapies to subject having certain genotypes/phenotypes, and to exclude therapies unlikely to be effective.
    Type: Application
    Filed: May 22, 2017
    Publication date: November 30, 2017
    Inventors: David A. BOOTHMAN, Julio MORALES, Edward MOTEA, Praveen PATIDAR
  • NON-NATURAL NUCLEOSIDES AS THERANOSTIC AGENTS
    Publication number: 20140329236
    Abstract: A theranostic agent for inhibiting translesion DNA replication comprises natural adenine ribose analog having formula I.
    Type: Application
    Filed: September 4, 2012
    Publication date: November 6, 2014
    Inventors: Anthony J. Berdis, Irene Lee, Edward Motea